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From the peanut gallery
Because the risk of anaphylaxis affects the quality of life of 
patients with peanut allergy, disease-modifying therapy is 
desperately needed. Although inhalant allergies and insect-
venom anaphylaxis have been successfully treated with 
immunotherapy in the past, previous attempts to utilize 
subcutaneous immunotherapy for peanut allergy have been 
plagued by severe adverse reactions. Thus, Anagnostou and 
colleagues examined the efficacy of oral immunotherapy 
for the treatment of peanut allergy in children in a random-
ized controlled crossover trial. Indeed, daily doses of 800 mg 
protein resulted in a clinically meaningful effect with a high 
incidence of desensitization, increases in threshold, and a 
significant improvement in quality of life. A total of 84% of 
participants in the first phase and 91% of participants in the 
second phase could tolerate ingestion of an equivalent of five 
peanuts. Raising the reactive threshold is key owing to acci-
dental reactions caused by contaminated and incorrectly 
labeled foods. (Lancet, published online 30 January 2014; 
doi.10.1016/S0140-6736(13)62301-6) Selected by H. Williams
Regulation of skin inflammation
Type 2 innate lymphoid cells (ILC2s) have been detected 
within mouse and human atopic lesional skin. Salimi and col-
leagues found that frequencies of these cells were elevated in 
lesional skin from atopic dermatitis (AD) patients compared 
with healthy skin and that ILC2s were expanded following 
allergen challenge. In response to IL-33, these cells migrated 
and released type 2 cytokines and amphiregulin, which has 
been implicated in barrier repair mechanisms. In addition, in 
the presence of E-cadherin, human ILC2s were inhibited via 
interaction with E-cadherin. These results suggest that low 
E-cadherin expression, which is characteristic of filaggrin 
insufficiency and AD, may promote ILC2 activation and high-
light a new potential mechanism for barrier sensing. Finally, 
these investigators demonstrated that the initiating cytokines 
IL-25 and IL-33 regulate ILC2s in the development of allergic 
skin inflammation. These factors, along with thymic stromal 
lymphopoietin, may have important therapeutic implications 
for treatment of atopic disease. (J Exp Med 210:2939–50, 
2013) Selected by L. Beck
It’s all in the details
Many studies of the complex autoimmune disease systemic 
sclerosis (SSc) have sought to elucidate its genetic compo-
nents. Genome-wide association studies have confirmed that 
the major histocompatibility complex (MHC) class II region 
is the most significant genetic region associated with SSc 
and have also identified multiple non-MHC loci. To take the 
next step in identifying the causal variants, discovering lower 
penetrance variants, and fine-tuning the mapping of these 
areas, an international group of collaborators formed the 
Immunochip Consortium to utilize a custom single-nucleotide 
polymorphism (SNP) genotyping array to provide high-density 
mapping of autoimmune disease–associated loci in a large 
European cohort. Overall, this study identified six amino acid 
positions and seven SNPs to explain the association of SSc 
with the HLA region, increased the number of genetic associa-
tions known for SSc, and shed light on the pleiotropic effects 
of shared autoimmune risk factors. (Am J Hum Genet 94:47–
61, 2014) Selected by J. Uitto
Related risk
Psoriasis, which affects 2–4% of the general population, is 
associated with diabetes, metabolic syndrome, and cardio-
vascular disease, and the notion of psoriatic nephropathy has 
been proposed based on case reports. Wan and colleagues 
recently investigated the risk of chronic kidney disease in a 
population-based cohort of psoriasis patients in the United 
Kingdom using the Health Improvement Network. Moderate 
to severe psoriasis was found to be an independent risk fac-
tor for moderate to advanced chronic kidney disease, and 
this increased risk was independent of traditional risk factors, 
including diabetes and cardiovascular disease. These findings 
support closer monitoring for renal insufficiency in patients 
with psoriasis that affects more than 3% of their body surface 
area and suggest caution with the use of nephrotoxic drugs in 
this population. (BMJ 347:f5961, 2013) Selected by T. Nijsten
Staging difficulties
Although the majority of cutaneous squamous-cell carci-
noma (CSCC) patients have an excellent prognosis, a subset 
carries increased risk of local recurrence, nodal metastasis, 
and disease-specific death. The goal of cancer staging is to 
separate patients into distinctive groups that are homoge-
neous and monotonous. The American Joint Committee on 
Cancer (AJCC) and the International Union against Cancer 
(UICC) published a revised tumor (T) staging system in 2010. 
In a recent study, Karia and colleagues compared these sys-
tems to the Brigham and Women’s Hospital (BWH) T staging 
system in a large cohort of patients with CSCC. Significant 
difficulties with the current staging systems were identified. 
UICC and AJCC staging failed to identify the high-risk sub-
set because these poor outcomes were categorized within a 
heterogeneous lower T stage group. BWH staging improved 
distinctiveness, homogeneity, and monotonicity over AJCC 
and UICC staging primarily by making a distinction in the T2 
population (T2a and T2b) to separate high-risk and low-risk 
tumors in this subtype. These findings will pave the way for 
additional staging modifications and description of optimal 
treatments for specifically defined high-risk tumors. (J Clin 
Oncol 32:327–34, 2014) Selected by T. NijstenJournal of Investigative Dermatology (2014) 134, 1188. doi:10.1038/jid.2014.131
